LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

IMDx Receives Certification to Develop, Manufacture IVD Devices

By LabMedica International staff writers
Posted on 21 Jun 2012
Intelligent Medical Devices (IMDx; Cambridge, United Kingdom) has received International Organization for Standardization (ISO) certification to design, develop, and manufacture in vitro diagnostic devices for the diagnosis of infectious diseases in molecular biology, and will obtain licenses to commercialize the tests in Canada.

IMDx underwent a stringent audit of its quality system to ISO 13485:2003 with the implementation of requirements from the Canadian Medical Devices Regulations. The audit included quality management system development, documentation review, preaudit, initial assessment, and clearance. The ISO 13485:2003 accreditation was received from the Laboratoire national de métrologie et d’essais (LNE/G-MED) and is accepted worldwide as the inclusive international standard that defines quality in the area of medical devices.

The IMDx portfolio of infectious disease diagnostics includes CE-marked tests for toxigenic Clostridium difficile, vancomycin-resistant enterococci, and Group B Streptococcus.

“Receiving this certification is a true testament to our dedication to making high quality products,” says Dr. Alice Jacobs, MD, chairman and CEO of IMDx. “Our mission at IMDx is to make a wide range of diagnostic tests available as broadly as possible. The ability to eventually commercialize our tests in Canada brings us closer to achieving the goal of improving healthcare worldwide.”

Related Links:
International Organization for Standardization
IntelligentMDX




Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
21 Jun 2012  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
21 Jun 2012  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
21 Jun 2012  |   Industry



PURITAN MEDICAL